Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by iA Global Asset Management Inc.

iA Global Asset Management Inc. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 91.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,950 shares of the medical research company's stock after selling 21,080 shares during the quarter. iA Global Asset Management Inc.'s holdings in Charles River Laboratories International were worth $360,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Versant Capital Management Inc boosted its position in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares during the period. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the last quarter. Tortoise Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International during the third quarter worth approximately $59,000. Finally, ORG Wealth Partners LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at $56,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Insider Activity at Charles River Laboratories International

In related news, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Down 2.8 %

NYSE:CRL traded down $4.71 on Tuesday, reaching $162.27. The stock had a trading volume of 266,254 shares, compared to its average volume of 724,610. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $273.57. The company has a market cap of $8.30 billion, a price-to-earnings ratio of 1,081.87, a P/E/G ratio of 4.54 and a beta of 1.45. The firm's fifty day moving average is $165.66 and its two-hundred day moving average is $183.49. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.46 earnings per share. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the topic of several research reports. Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price target for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Bank of America reduced their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Finally, Barclays dropped their target price on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).